Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07821944 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)

StatusNot Yet Recruiting
PhasePhase 3
Started2026-10-16
View on ClinicalTrials.gov ↗
Merck (MSD)
401 trials monitored
See 24 trials at risk
Researchers are looking for new ways to treat high cholesterol. Cholesterol is a type of fat in the blood. Enlicitide (also known as enlicitide decanoate or MK-0616), the study medicine, is in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C). LDL-C is sometimes called "bad cholesterol." The goal of this study is to learn if enlicitide works better than placebo to lower the amount of LDL-C in a person's blood. Researchers also want to learn about the safety of enlicitide and if people tolerate it.
Trial Details
NCT Number NCT07821944
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Hyperlipidemia, Hypercholesterolemia
Enrollment 150 participants
Start Date 2026-10-16
Primary Completion 2027-11-26 (estimated)
Study Completion 2027-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-09-16